ORCID Profile
0000-0001-8008-9727
Current Organisations
Universiteit Maastricht
,
Karolinska Institutet
,
AmsterdamUMC location VUmc
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: Wiley
Date: 08-12-2021
DOI: 10.1002/ALZ.12512
Abstract: The evidence for characteristics of persons with subjective cognitive decline (SCD) associated with amyloid positivity is limited. In 1640 persons with SCD from 20 Amyloid Biomarker Study cohort, we investigated the associations of SCD‐specific characteristics (informant confirmation, domain‐specific complaints, concerns, feelings of worse performance) demographics, setting, apolipoprotein E gene ( APOE ) ε4 carriership, and neuropsychiatric symptoms with amyloid positivity. Between cohorts, amyloid positivity in 70‐year‐olds varied from 10% to 76%. Only older age, clinical setting, and APOE ε4 carriership showed univariate associations with increased amyloid positivity. After adjusting for these, lower education was also associated with increased amyloid positivity. Only within a research setting, informant‐confirmed complaints, memory complaints, attention/concentration complaints, and no depressive symptoms were associated with increased amyloid positivity. Feelings of worse performance were associated with less amyloid positivity at younger ages and more at older ages. Next to age, setting, and APOE ε4 carriership, SCD‐specific characteristics may facilitate the identification of amyloid‐positive in iduals.
Publisher: American Medical Association (AMA)
Date: 09-2019
Publisher: Wiley
Date: 29-04-2019
Publisher: Wiley
Date: 02-05-2014
Publisher: Springer Science and Business Media LLC
Date: 29-10-2020
DOI: 10.1186/S13195-020-00706-2
Abstract: Impairment in daily functioning is a clinical hallmark of dementia. Difficulties with “instrumental activities of daily living” (IADL) seem to increase gradually over the course of Alzheimer’s disease (AD), before dementia onset. However, it is currently not well established how difficulties develop along the preclinical and prodromal stages of AD. We aimed to investigate the trajectories of decline in IADL performance, as reported by a study partner, along the early stages of AD. In a longitudinal multicenter study, combining data from community-based and memory clinic cohorts, we included 1555 in iduals (mean age 72.5 ± 7.8 years 50% female) based on availability of amyloid biomarkers, longitudinal IADL data, and clinical information at baseline. Median follow-up duration was 2.1 years. All amyloid-positive participants ( n = 982) were classified into the National Institute on Aging–Alzheimer’s Association (NIA-AA) clinical stages ranging from preclinical AD (1) to overt dementia (4+). Cognitively normal amyloid-negative in iduals ( n = 573) served as a comparison group. The total scores of three study-partner reported IADL questionnaires were standardized. The rate of decline in cognitively normal (stage 1) in iduals with and without abnormal amyloid did not differ ( p = .453). However, from stage 2 onwards, decline was significantly faster in in iduals on the AD continuum ( B [95%CI] = − 0.32 [− 0.55, − 0.09], p = .007). The rate of decline increased with each successive stage: one standard deviation (SD) unit per year in stage 3 (− 1.06 [− 1.27, − 0.85], p .001) and nearly two SD units per year in stage 4+ (1.93 [− 2.19, − 1.67], p .001). Overall, results were similar between community-based and memory clinic study cohorts. Our results suggest that the rate of functional decline accelerates along the AD continuum, as shown by steeper rates of decline in each successive NIA-AA clinical stage. These results imply that incremental changes in function are a meaningful measure for early disease monitoring. Combined with the low-cost assessment, this advocates the use of these functional questionnaires for capturing the effects of early AD-related cognitive decline on daily life.
Publisher: Cold Spring Harbor Laboratory
Date: 22-03-2023
DOI: 10.1101/2023.03.21.23287468
Abstract: Brain development and maturation leads to grey matter networks that can be measured using magnetic resonance imaging. Network integrity is an indicator of information processing capacity which declines in neurodegenerative disorders such as Alzheimer disease (AD). The biological mechanisms causing this loss of network integrity remain unknown. Cerebrospinal fluid (CSF) protein biomarkers are available for studying erse pathological mechanisms in humans and can provide insight into decline. We investigated the relationships between 10 CSF proteins and network integrity in mutation carriers (N=219) and noncarriers (N=136) of the Dominantly Inherited Alzheimer Network Observational study. Abnormalities in Aβ, Tau, synaptic (SNAP-25, neurogranin) and neuronal calcium-sensor protein (VILIP-1) preceded grey matter network disruptions by several years, while inflammation related (YKL-40) and axonal injury (NfL) abnormalities co-occurred and correlated with network integrity. This suggests that axonal loss and inflammation play a role in structural grey matter network changes. - Abnormal levels of fluid markers for neuronal damage and inflammatory processes in CSF are associated with grey matter network disruptions. - The strongest association was with NfL, suggesting that axonal loss may contribute to disrupted network organization as observed in AD. - Tracking biomarker trajectories over the disease course, changes in CSF biomarkers generally precede changes in brain networks by several years.
Publisher: Springer Science and Business Media LLC
Date: 17-05-2019
Publisher: Oxford University Press (OUP)
Date: 08-09-2020
Abstract: Determinants of cognitive functioning in in iduals aged 90 years and older, the oldest-old, remain poorly understood. We aimed to establish the association of risk factors, white matter hyperintensities (WMHs), hippoc al atrophy, and amyloid aggregation with cognition in the oldest-old. We included 84 in iduals without cognitive impairment and 38 in iduals with cognitive impairment from the EMIF-AD 90+ Study (mean age 92.4 years) and tested cross-sectional associations between risk factors (cognitive activity, physical parameters, nutritional status, inflammatory markers, and cardiovascular risk factors), brain pathology biomarkers (WMH and hippoc al volume on magnetic resonance imaging, and amyloid binding measured with positron emission tomography), and cognition. Additionally, we tested whether the brain pathology biomarkers were independently associated with cognition. When applicable, we tested whether the effect of risk factors on cognition was mediated by brain pathology. Lower values for handgrip strength, Short Physical Performance Battery (SPPB), nutritional status, HbA1c, and hippoc al volume, and higher values for WMH volume and amyloid binding were associated with worse cognition. Higher past cognitive activity and lower body mass index were associated with increased amyloid binding, lower muscle mass with more WMH, and lower SPPB scores with more WMH and hippoc al atrophy. The brain pathology markers were independently associated with cognition. The association of SPPB with cognition was partially mediated by hippoc al volume. In the oldest-old, physical parameters, nutritional status, HbA1c, WMH, hippoc al atrophy, and amyloid binding are associated with cognitive impairment. Physical performance may affect cognition through hippoc al atrophy. This study highlights the importance to consider multiple factors when assessing cognition in the oldest-old.
Publisher: Springer Science and Business Media LLC
Date: 20-08-2018
Publisher: Springer Science and Business Media LLC
Date: 17-04-2017
Publisher: Informa UK Limited
Date: 27-10-2017
Publisher: Elsevier BV
Date: 07-2017
DOI: 10.1016/J.ARR.2017.02.006
Abstract: Reference values to define cognitive impairment in in iduals aged 90 years and older are lacking. We systematically reviewed the literature to determine the level of cognitive functioning of in iduals aged 90 years and older without dementia. The search identified 3972 articles of which 20 articles were included in the review. We calculated mean cognitive test scores and cut-off scores for cognitive tests published in two or more articles. The mean cognitive test scores (SD)/cut-off scores for in iduals aged 90 years and older without dementia of the five most commonly used cognitive tests were: MMSE: 26.6 (2.6)/23.3 points, Digit Span forward: 5.9 (1.8)/3.6 digits, Digit Span backward: 4.4 (1.6)/2.4 digits, TMT-A: 85.8 (42.5)/140.2s and TMT-B: 220.3 (99.2)/347.3s. We provided mean cognitive test scores and cut-off scores that will improve the diagnostic process of cognitive impairment in in iduals aged 90 years and older.
Publisher: Oxford University Press (OUP)
Date: 14-08-2019
Abstract: The prevalence of brain pathologies increases with age and cognitive and physical functions worsen over the lifetime. It is unclear whether these processes show a similar increase with age. We studied the association of markers for brain pathology cognitive and physical functions with age in 288 cognitively normal in iduals aged 60–102 years selected from the cross-sectional EMIF-AD PreclinAD and 90+ Study at the Amsterdam UMC. An abnormal score was consistent with a score below the 5th percentile in the 60- to 70-year-old in iduals. Prevalence of abnormal scores was estimated using Generalized Estimating Equations (GEE) models. The prevalence of abnormal handgrip strength, the Digit Symbol Substitution Test, and hippoc al volume showed the fastest increase with age and abnormal MMSE score, muscle mass, and amyloid aggregation the lowest. The increase in prevalence of abnormal markers was partly dependent on sex, level of education, and amyloid aggregation. We did not find a consistent pattern in which markers of brain pathology cognitive and physical processes became abnormal with age.
Publisher: Springer Science and Business Media LLC
Date: 23-04-2020
DOI: 10.1007/S10654-020-00633-4
Abstract: The Dementias Platform UK Data Portal is a data repository facilitating access to data for 3 370 929 in iduals in 42 cohorts. The Data Portal is an end-to-end data management solution providing a secure, fully auditable, remote access environment for the analysis of cohort data. All projects utilising the data are by default collaborations with the cohort research teams generating the data. The Data Portal uses UK Secure eResearch Platform infrastructure to provide three core utilities: data discovery, access, and analysis. These are delivered using a 7 layered architecture comprising: data ingestion, data curation, platform interoperability, data discovery, access brokerage, data analysis and knowledge preservation. Automated, streamlined, and standardised procedures reduce the administrative burden for all stakeholders, particularly for requests involving multiple independent datasets, where a single request may be forwarded to multiple data controllers. Researchers are provided with their own secure ‘lab’ using VMware which is accessed using two factor authentication. Over the last 2 years, 160 project proposals involving 579 in idual cohort data access requests were received. These were received from 268 applicants spanning 72 institutions (56 academic, 13 commercial, 3 government) in 16 countries with 84 requests involving multiple cohorts. Projects are varied including multi-modal, machine learning, and Mendelian randomisation analyses. Data access is usually free at point of use although a small number of cohorts require a data access fee.
Publisher: Wiley
Date: 11-2018
DOI: 10.1002/ANA.25333
Publisher: Elsevier BV
Date: 05-2017
DOI: 10.1016/J.NEUROBIOLAGING.2017.01.013
Abstract: Few studies have examined the relationship between CSF and structural biomarkers, and cognitive function in MCI. We examined the relationship between cognitive function, hippoc al volume and cerebrospinal fluid (CSF) Aβ
Publisher: Springer Science and Business Media LLC
Date: 28-04-2020
DOI: 10.1186/S12877-020-01556-1
Abstract: Ocular imaging receives much attention as a source of potential biomarkers for dementia. In the present study, we analyze these ocular biomarkers in cognitively impaired and healthy participants in a population aged over 90 years (= nonagenarian), and elucidate the effects of age on these biomarkers. For this prospective cross-sectional study, we included in iduals from the EMIF-AD 90+ study, consisting of a cognitively healthy ( N = 67) and cognitively impaired group ( N = 33), and the EMIF-AD PreclinAD study, consisting of cognitively healthy controls aged ≥60 ( N = 198). Participants underwent Optical Coherence Tomography (OCT) and fundus photography of both eyes. OCT was used to asses total and in idual inner retinal layer thickness in the macular region (Early Treatment Diabetic Retinopathy Study circles) as well as peripapillary retinal nerve fiber layer thickness, fundus images were analyzed with Singapore I Vessel Assessment to obtain 7 retinal vascular parameters. Values for both eyes were averaged. Differences in ocular biomarkers between the 2 nonagenarian groups were analyzed using linear regression, differences between the in idual nonagenarian groups and controls were analyzed using generalized estimating equations. Ocular biomarkers did not differ between the healthy and cognitively impaired nonagenarian groups. 19 out of 22 ocular biomarkers assessed in this study differed between either nonagenarian group and the younger controls. The ocular biomarkers assessed in this study were not associated with cognitive impairment in nonagenarians, making their use as a screening tool for dementing disorders in this group limited. However, ocular biomarkers were significantly associated with chronological age, which were very similar to those ascribed to occur in Alzheimer’s Disease.
Publisher: Springer Science and Business Media LLC
Date: 26-11-2018
Publisher: Wiley
Date: 13-12-2019
Publisher: Public Library of Science (PLoS)
Date: 03-09-2015
No related grants have been discovered for Pieter Jelle Visser.